Compare Consolidated Edison, Inc. (ED) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs 10X Genomics Inc — how do they compare? Consolidated Edison, Inc. trades at $106.07 (market cap $39.20B), while 10X Genomics Inc trades at $81 (market cap $10.07B). The key difference: Consolidated Edison, Inc. is far larger — about 3.9× 10X Genomics Inc's market cap, and Consolidated Edison, Inc. pays a 3.31% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and 10X Genomics Inc for 91 Days on average.
| ED | TXG | |
|---|---|---|
Market Cap | $39.20B | $10.07B |
Volume | 2,142,900 | 5,657,286 |
Sector | Utilities | Health |
52-Week High | $115.46 | $97.74 |
52-Week Low | $95.37 | $11.48 |
Typical Hold Time | 75 Days | 91 Days |
Enterprise Value | $66.05B | $9.59B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $105.94, up 1.23% today, near the consensus price target of $106.33. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages, while fundamentals reflect steady utility performance with 2025 revenue of $16.92B and net income of $2.02B. Recent news highlights its $24.8B economic impact in New York and upcoming investor webcast, reinforcing its stable dividend aristocrat status.
ED offers a defensive investment with a reliable dividend and moderate growth, but faces risks from high debt levels and interest expenses. Analyst sentiment is cautious with 62.96% hold ratings, suggesting limited near-term upside despite solid cash flow generation. The stock's appeal lies in its income stability amid economic uncertainty, though execution on capital expenditures remains key to sustaining growth.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
